Precision Medicine:
Redefining the Future of Healthcare

30 September - 01 October 2025 | London, UK

Delivering Personalized Treatments

Join us for Biomarkers & Precision Medicine UK, an immersive event now in its 20th year, spotlighting the latest trends and tools in biomarker research. This year’s agenda also includes dedicated programmes on Spatial Biology for Precision Medicine and Digital Pathology & AI. The event gathers leading experts from global pharmaceutical companies, pioneering biotech firms & startups, and leading academic & healthcare institutions, all contributing to various therapeutic areas and stages of drug development, clinical trials, and precision patient treatments.

Biomarkers & Precision Medicine Top Section Image

Explore the Biomarkers & Precision Medicine 2025 Programme

Select the area of most interest from the icons below

Precision Medicine Awards 2025 Logo (Light)

Join us at the Precision Medicine Awards 2025, for an evening dedicated to celebrating visionary institutions and individuals who are driving innovation & excellence in Precision Medicine. Held at the stunning Grade II listed Assembly Hall at Church House - just a 3 minute walk from the conference venue - this prestigious event offers a unique timely opportunity to celebrate and honour groundbreaking achievements in the industry which are accelerating targeted treatments and transforming patient outcomes. 

Lights, Camera, Action!

Explore our curated photo gallery of standout moments from NextGen Omics & Spatial Biology US 2025. See if you can spot yourself!

NextGen Biomed 2025

Advancing Therapeutic Innovation Through Multi-Omics Research  

NextGen Omics & Spatial Biology connects thought leaders, researchers, and experts with pharmaceutical & biotech representatives to discuss the latest innovations across the fields of multi-omics. 

There are three dedicated programmes running across two full days, which together will explore multi-omics from technological development to therapeutic applications and analysis, making this a must-attend event for anyone working in clinical diagnostics, single cell & spatial biology. 

Hear from past attendees of last year's Biologics 2024 conference

Explore the NextGen Omics & Spatial Biology US 2025 Programme

Antibody Society

NextGen Biomed 2025 is supported by our
Scientific Programme Partner The Antibody Society

Biom & Pre Med About Image

About

Discover our ecosystem of channels for the precision medicine community

Biom & Pre Med Attend Image

Attend

Join the wave of precision medicine innovation. Secure your spot today!

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers

Biom & Pre Med Whats On Image

What's On

Explore dynamic panels, engaging roundtables, and hands-on workshops

Key Themes

We asked key opinion leaders which breakthroughs will shape the future of precision medicine. The answer? A shift beyond genomics to multi-omics—integrating proteomics, metabolomics, and spatial biology to decode disease at every level. AI is transforming immunohistochemistry, sharpening biomarker design and pathology analysis. Multi-modal data and multiplexing are exposing hidden cancer circuitry, driving smarter target discovery. As AI-driven innovations navigate IVDR regulations, precision medicine is moving from promise to reality, bringing sharper diagnostics, better therapies, and truly individualized care.

Key Event Highlights

An unmissable journey awaits you: From celebrated keynote speakers and insightful fireside chats, to the brand new Awards Dinner. Discover the moments that will transform your Biomarkers & Precision Medicine experience. 

What's been happening at NextGen Omics & Spatial Biology US 2025?

Have a peek into the dynamic panels, engaging roundtables, and hands-on workshops happening in Boston - right now!

spatial biology Track keynote address 
 Spatial Multi-Omics For Target-To-Disease Linkage In Inflammatory Diseases

MARINA BLECK, Principal Scientist, Boehringer Ingelheim

Marina discussed the use of multi omics for faster Faster Target-to- Disease Link (T2DL) with increased confidence and how they can leverage Spatial Biology to enhance the ability to derive insight from human disease tissues.  Finally the Importance of FFPE Tissue Quality for Spatial Biology was discussed with the use of QC scoring to determine which FFPE tissue gives the best spatial transcriptomics results.

spatial biology day one, track 6 
Spatial Biology As A Discovery Pathway

EMRE ARSLAN, Takeda

Emre Arslan from Takeda gave a talk about the use of Spatial Biology as a discovery pathway. First of all providing an update on the current landscape for spatial technologies then analysing how spatial technologies can be used in clinical trial design - such as the ability to identify previously unknown cell types, interactions and microenvironments and providing an ideal foundation for training better AI models. 

day 2 keynote
Single Cell into Spatial and Beyond: Landscape in 2025 and What’s Next?

JASMINE PLUMMER, Director, St Jude Children's Research Hosptial

Jasmine Plummer's day 2 keynote focused on Single cell into spatial and beyond.  "The reason we are in this room is because it’s cutting edge" which is why the single cell and spatial field growing exponentially.

Future directions for the technology include Low throughput, clinical trials, other organisms, more tissue types, epigenomics

Spatial multi-omics, track 4 Keynote
Rapid Single-Cell Spatial Proteomics by Spatial MIST

JUN WANG, Associate Professor, Multiplex Biotechnology Laboratory, Department of Biomedical Engineering, Stony Brook University

"Simpler but more powerful than flow and imaging cytometry"

MIST Technology provides100 times more information than flow cytometry and currently the highest multiplexity is up to 500 markers/ cell.

Single cell track keynote address
Panel Application Of Single Cell Omics In Clinical Monitoring

PRIYA CHOCKALINGAM, Vice President, Head of Clinical BioAnalytics & Translational Sciences, Beam Therapeutics

Priya's talk focused on Genome Editing Technologies for Gene & Cell Therapy and how cell & gene therapies require a specialized regulatory approach compared to other modalities. Appropriate assessments should therefore be put in place in both nonclinical and clinical stages to address safety concerns.

Various methods to assess off-target editing effects have evolved in the last decade. However, limitations remain in balancing accuracy vs sensitivity of these new techniques.

The direct assessment of off-target effects in vivo and in patients is particularly challenging.

Novel single-cell technologies enable quantitation/co-occurrence of on-/off-target editing through patient time-course of treatment

single cell  
Comparative Insights In Single Cell RNA-seq & Advances In Large-Scale Multimodal Profiling

ZORA MODRUSAN, Senior Director NGS, Genentech

Zora focused on both key insights and future directions of single cell RNA-Seq.  scRNA-seq technologies were evaluated and the differences in performance across various metrics such as sensitivity, throughput and cost were compared across different systems.

The Overloading And unpacKing (OAK) method provides a reliable solution for large-scale molecular profiling that incorporates multiple data modalities.

Moving forward they will continue to evaluate the latest scRNA-seq kits to understand differences and guide optimal performance. Zora would also like to enhance OAK's capabilities by integrating additional modalities and applying the platform to a wide range of biological systems.

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful private roundtables, to an exclusive gala dinner. Discover the moments that will transform your NextGen Omics & Spatial experience. 

Who is Speaking at Biomarkers & Precision Medicine 2025?

Meet Our Expert Speakers

Biomarkers & Precision Medicine 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Elena Miranda
Director, Non Clinical Histology,
GSK
Espen Walker
Global Head of Medical Diagnostics,
AstraZeneca
Jeroen van der Laak
Professor of Computational Pathology,
Radboudumc
Maria Orr
Head of Precision Medicine and Biosamples,
AstraZeneca
Mark Caufield
Professor,
Queen Mary University of London
Matt Brown
Chief Scientific Officer,
Genomics England
Paul van Diest
Professor and Head, Department of Pathology,
University Medical Center Utrecht
Stephanie Craig
Lecturer,
Queen's University Belfast
Svetlana Mukhina
Director Global Regulatory Affairs, CDx,
Merck Group
Virginia Savova
Senior Director, Cell Targeted Precision Medicine,
AstraZeneca
Alain Van Gool
Professor Personalized Healthcare,
Radboud University Medical Center
Amonida Zadissa
Associate Director of Informatics,
UK Dementia Research Institute
Ana Hidalgo Sastre
Director,
AstraZeneca
Antonina Mitrofanova
Associate Professor,
Rutgers University
Arman Rahman
Assistant Professor,
University College Dublin
Arthur Lewis
Director,
AstraZeneca
Azam Hamidinekoo
Associate Director,
AstraZeneca
Belinda Nedjai
Associate Professor,
Queen Mary University Of London
Bernd Wollscheid
Professor,
ETHZ
Chris Bray
Head Global Regulatory Affairs,
Merck & Cie KmG
Daniel Strasser
Director,
Novartis
Danny Kaye
Lead Digital Pathology Scientist,
Leeds Teaching Hospitals NHS Trust, NPIC
David Clark
Consultant Haematopathologist,
Nottingham University Hospitals NHS Trust
David Snead
Pathologist,
Histofy AI
David Krige
Head of Translational Sciences,
Accession Therapeutics
Debayan Mukherjee
Principal Scientist,
GSK
Emanuela Oldoni
Scientific Programme Manager- Biomarkers,
EATRIS
Emmanuel Valentin
Vice President, Translational Medicine,
Imcheck Therapeutics
Fan Liu
Professor,
FMP Berlin
Francesca Trapani
Scientific Director,
Boehringer Ingelheim
Gayle Marshall
Head of Biomarkers,
Catapult Medicines Discovery
Giovanna Lalli
Director,
LifeArc
Harpreet Saini
Senior Director Bioinformatics,
Astex Pharmaceuticals
Helen Graves
Principal Scientist,
Alchemab Therapeutics
Henoch Hong
Associate Director,
Merck & Cie KmG
Huw Bannister
Senior Director,
AstraZeneca
Inês Sequeira
Postdoctoral,
Queen Mary University of London
Irene Del Molino del Barrio
Principal Scientist,
GSK
James Schofield
Chief Executive Officer,
TopMD
Jan-Philipp Mallm
Head of Single Cell Open Lab, DKFZ,
DKFZ
Jean-Baptiste Lugagne
Group Leader & Assistant Professor,
Centre for Medicines Discovery
Jean-Christophe Olivo-Marin
Professor & Head of the Quantitative Image Analysis Unit,
Institute Pasteur
Jens Kieckbusch
Director,
GSK
Jim Eyles
Director,
AstraZeneca
Jimmy Bell
Professor,
University of Westminster
Jo Taylor
Founder,
METUPUK
Joanna Janus
Research Programme Manager (Early Detection and Prevention),
Cancer Research UK
Joao Pinto
Surgical Pathologist,
Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup)
Johan Luthman
Executive Vice President,
Lundbeck
Jose Izarzugaza
Director of Biomarker and MoA Insights,
Novo Nordisk
Joshua Atkins
Senior Genomic Epidemiologist,
Cancer Epidemiology Unit (CEU) - University of Oxford
Karl Smith-Byrne
Senior Molecular Epidemiologist, Cancer Epidemiology Unit (CEU),
Centre for Medicines Discovery, University of Oxford
Kazumasa Kanemaru
Postdoctoral Researcher,
Teichmann Group, Cambridge Stem Cell Institute, University of Cambridge
Kiri Granger
Chief Scientific Officer,
Monument Therapeutics
Laurent Audoly
Co-Founder,
PriveBio
Liz Harrington
Executive Director,
Astrazeneca
Mani Mudaliar
Director, Quantitative Biomarkers,
Recursion
Manuel Salto-Tellez
Professor,
The Institute of Cancer Research
Manuela Cerina
Scientific Director of Neurodegeneration,
LifeArc
Maria Laura Garcia Bermejo
Scientific Director & Co-Chair,
Ramon y Cajal Health Research Institute (IRYCIS)
Marisca Marian
Oncology Market Access Strategy Leader,
Bayer AG
Markus Schulze
Senior Scientist,
Merck & Cie KmG
Martin Isabelle
Associate Director, Tumour Profiling and Mechanistic Biology, Translational Sciences,
Adaptimmune
Matthew Humphries
Director,
NHS
Michael Zaiac
Head,
Daiichi Sankyo
Michael Cannarile
Head of Biomarkers, Early Development Oncology (EDO), Pharma Research & Development (pRED),
Roche
Miguel Souto
Director,
Idibell
Mike Messenger
Head of Regulatory Strategy,
BIVDA
Miro Venturi
Operating Partner,
ARCHIMED
Muhammad Aslam
Clinical Director,
Velindre University
Nathalie Banner
Director of Ethics,
Genomics England
Neil Humphryes-Kirilov
Associate Director,
C4X Discovery
Nitin Jain
Director, Franchise Project Management,
AstraZeneca
Olga Nissan
Chief Executive Officer,
Protica Bio
Peter Groenen
Head of Translational Science,
Cerebrum DAO
Prakash Ramachandran
Professor,
University of Edinburgh
Raffaele Adolfo Calogero
Professor,
University of Torino
Rahul Deb
Consultant Histopathologist, Lead Breast Pathologist,
University Hospitals of Derby and Burton NHS Foundation
Richard Festenstein
Clinical Professor,
Imperial College London
Roya Esat Dabestani
Precision Medicine Lead,
Innovate UK Business Connect
Sonali Natu
Clinical Lead,
Incisive Health
Thomas Jensen
Chief Executive Officer,
Allarity Therapeutics
Thomas Hach
Global Program Clinical Head,
Novartis
Valerie Taly
Group Leader,
University of Paris Descartes
Victoria Goss
Head of Early Diagnosis and Translational Group,
University of Southampton
Vihanga Pahalawatta
Director of Regulatory Affairs Companion Diagnostics,
AbbVie
Wanderson Dos Santos Trindade
Director,
Daiichi Sankyo
Wolfgang Breitwieser
Head of Molecular Biology,
Cancer Research -UK Manchester Institute

Interested in Sponsoring NextGen Omics & Spatial Biology US 2025?

Become a driving force in accelerating the next generation of multi-omics-based treatments. NextGen Omics & Spatial Biology US offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of genomic medicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring Biomarkers & Precision Medicine 2025?

Become a driving force in accelerating the next generation of personalized treatments. Biomarkers & Precision Medicine 2025 offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of precision medicine today.

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

New Opportunities

The Start-up Zone

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs. 

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

To get involved, apply today and our Start-Up Lead will be in touch to discuss further.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.

To be eligible for inclusion, you must meet the following criteria:

•    0 – 5 years operating
•    0 – 30 employees
•    Pre-Series A funding

Successful applicants will receive as part of their package:

•    2 full conference passes
•    10-minute pitch on the Start-Up Stage
•    1x1m space in Start-Up Zone: cocktail table provided, start-up to bring 1x pull-up banner
•    Logo featured on website & event platform as a participating start-up
•    Ability to arrange 1:1 meetings via to the congress app

Interdisciplinary Learning

The Collaboration Hub

Interdisciplinary learning and knowledge share is key to driving Precision Medicine. Our Collaboration Hub sessions will provide a platform to enable experts and innovators from diverse complimentary fields to foster collaboration, hear fresh perspectives, encourage innovation, break down silos and address specific challenges within the field.

Each invitation only focused session will last one hour and house a maximum of 15 diverse specialists alongside a high-level moderator to facilitate discussion.

Moderated by: Vihanga Pahalawatta, Director Regulatory Affairs Companion Diagnostics, Abbvie 

Discussion Points: How to prepare for and adopt to shifts in regulations related to personalized health care, whilst streamlining processes

Invited Specialists: Regulatory officials, patient representatives, clinicians

Moderated by: Katherine Freeman, Senior Portfolio Manager, Digital Health, EPSRC

Discussion Points: How to maximize the benefit of AI in precision medicine and explore challenges around managing risk, ethical considerations, regulatory compliance and integrating into existing systems

Invited Specialists: AI specialists, data scientists, clinicians, regulatory officials, bioethicists, IT infrastructure experts

Discussion Points: How to align stakeholders and design strategies to overcome the challenges in adopting precision medicine technologies, such as cost, accessibility, technology transfer and integration into clinical workflows.

Invited specialists: Technology developers, implementation specialists, knowledge/ technology transfer, healthcare administrators, clinicians, regulatory officials

Moderated by: Roya Esat-Dabestani, Precision Medicine Lead, Innovate UK Business Connect

Discussion Points: Identifying the barriers to translating research findings into clinical practice and exploring strategies to improve collaboration and align academic research with clinical needs, regulatory requirements and healthcare systems

Invited Specialists: Academic researchers, clinicians, healthcare administrators, technology/ knowledge transfer, regulatory officials, translational medicine experts

Discussion Points: Designing strategies to improve integration and analysis of diverse data sources (genomics, proteomics, patient health records) and also the sharing of datasets internally and externally to further precision medicine research

Invited Specialists: Data scientists, bioinformaticians, clinicians, IT infrastructure experts

Moderated by: Natalie Banner, Director of Ethics, Genomics England

Discussion Points: How to create ethical guidelines and legal frameworks for responsible genetic data use in precision medicine. 

Invited Specialists: Bioethicists, legal experts, geneticists, patient advocates, government policy makers
Roundtable (Circle)

Plan Your Visit

QEII
Broad Sanctuary, London SW1P 3EE

Located in the heart of Westminster, the Queen Elizabeth II Centre is just minutes from three major Underground lines, Jubilee, District, and Circle via nearby Westminster and St. James’s Park stations. The venue is within walking distance of key National Rail stations including Charing Cross, Victoria, and Waterloo, and offers excellent connections to London City and Gatwick airports. Set opposite Westminster Abbey and close to Parliament Square, the QEII Centre is ideally placed for both business and leisure visitors. While there is no public parking on-site, Blue Badge holders may park on the forecourt (by prior arrangement), with public parking available nearby. 

 

 

By Air  

London City Airport  The QEII Centre is easily accessible from London City Airport via the DLR. Take the DLR to Bank station, then transfer to the Circle or District line to Westminster. From Westminster station, it's a short 5-minute walk to the Centre. The journey costs between £3.50 and £5, depending on time and payment method. Alternatively, a taxi will take approximately 30 minutes and cost around £40–£45, depending on traffic. 

 

London Gatwick Airport  Take a Thameslink train from Gatwick to London Bridge (around 35 minutes), then transfer to the Jubilee line for Waterloo or Westminster. From Westminster station, it’s just a 5-minute walk to the QEII Centre. A taxi from Gatwick typically takes 60–90 minutes, with fares ranging from £65 to £85. 

 

Heathrow Airport – From Heathrow Airport, take the Elizabeth Line to Bond Street, then transfer to the Jubilee line to Westminster Station, which is a short 5 minute walk to the QEII Centre. The Piccadilly Line to Hammersmith switching to the District Line to Westminster is also another route which can be taken. A taxi from Heathrow to the venue takes around 45 – 60 minutes and can cost from £40 - £80.  

 

 

By Underground and Bus 

St. James’s Park is just a four-minute walk from the Queen Elizabeth II Centre and is served by the Circle and District lines. However, please note that this station does not offer step-free access, which may be important for those with mobility needs. Alternatively, Westminster Station is approximately a five-minute walk away and provides access to the Circle, District, and Jubilee lines. Westminster is a step-free station and offers accessible routes suitable for passengers with limited mobility. 

 

If arriving via Westminster Station, exit through Exit 6. This leads into an underground tunnel that emerges near Parliament Square. Once at street level, continue onto Whitehall, then turn left into Parliament Square. From there, cross the road and turn right onto Broad Sanctuary. The Queen Elizabeth II Centre will be on your right, directly opposite Westminster Abbey. 

 

For those travelling by bus, routes 11, 88, and 148 all serve the area around Parliament Square. These buses will drop passengers either directly outside Westminster Abbey or within close proximity to it, offering convenient access to the venue. 

 

 

By Rail  

The nearest National Rail station is Charing Cross, approximately a 12-minute walk from the QEII Centre. Victoria Station is also within walking distance, taking around 14 minutes on foot, while Waterloo Station is slightly further, at about an 18-minute walk. All three stations offer excellent transport links across London and beyond. 

 

 

By Car  

Leave the A4 at the Lancaster Place/Aldwych exit and continue onto the Strand. At Trafalgar Square, take the third exit onto Northumberland Avenue. Follow it to Victoria Embankment, then turn right. Continue briefly, then turn left onto Bridge Street. At Parliament Square, bear left onto Broad Sanctuary. The Queen Elizabeth II Centre will be on your right, opposite Westminster Abbey. Nearby public parking is available.  

 

 

Parking 

The QEII Centre does not offer public car parking facilities. However, Blue Badge holders are permitted to park on the Centre’s forecourt free of charge, subject to availability. Visitors are advised to call ahead on +44 20 7798 4000 to confirm access. Disabled passengers arriving by taxi or other vehicles may also be dropped off on the forecourt. For other visitors, JustPark offers nearby parking spaces, with prices starting from £3.30. Please see here.  

 

 

Oxford Global does not have any contracted rooms at the QEII. 

Below is a list of nearby hotels that you may find convenient for your stay:

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2026, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biomarkers & Precision Medicine 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Interested in Biomarkers & Precision Medicine 2025?